Accelerated evaluation of drug

The European Medicines Agency has acknowledged the huntingtin lowering drug, RG6042 (previously known as IONIS-HTTRx), as a possible therapy that may significantly improve patients’ quality of life and granted Priority Medicine designation. Read more: GROUNDBREAKING RESULTS! In other words, with the “PRIME” (PRIority MEdicine) designation, the European Medicines Agency will assist Read more…

New drug for HD approved in USA

Exciting news for the Huntington’s disease (HD) community! The USA drug regulator, the FDA, has approved a new drug in the treatment of HD. Its commercial name is Austedo, but the drug was previously known as Deutetrabenazine. It originates from Tetrabenazine which is used to treat chorea – the jerky movements – often found Read more…